Brandes et al.37 showed, by using tissue biopsy samples from 103 patients with GBM, that patients with methylation of the MGMT gene promoter had higher rates of pseudoprogression (91%) than patients with unmethylated MGMT (41%), as shown by MRI. The gene discussed is MGMT; the disease is glioblastoma.